. 2023 Apr 5;12(3):727–749. doi: 10.1007/s40120-023-00467-8

Table 1.

General characteristics of clinical trials in DLB as of September 27, 2022

Clinical trial phase	Number of clinical trials	Status			Classification		Repurposed agents
Clinical trial phase	Number of clinical trials	Completed	Active^a	Other status	DMT	Symptomatic	Repurposed agents
Phase3	7 (17.5%)	6 (86%)	1 (14%)	0	0	7 (100%)	7 (100%)
Phase 2	31 (77.5%)	15 (48.4%)	8 (25.8%)	8^b (25.8%)	8 (25.8%)	23 (74.2%)	16 (51.6%)
Phase 1	2 (5%)	0	0	2^c (100%)	2 (100%)	0	2 (100%)
Total	40	21 (52.5%)	9 (22.5%)	10 (27%)	10 (25%)	30 (75%)	25 (65%)

^aRecruiting, Active/not recruiting

^bWithdrawn = 3, pending = 2, not recruiting = 2, terminated = 1

^cNot yet recruiting = 2